Preclinical and clinical effects of mistletoe against breast cancer
Breast cancer is among the most frequent types of cancer in women worldwide. Current conventional treatment options are accompanied by side effects. Mistletoe is amongst the important herbal medicines traditionally used as complementary remedies. An increasing number of studies have reported antican...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Published: |
2014
|
| Subjects: |
| _version_ | 1796859972000153600 |
|---|---|
| author | Marvibaigi, Mohsen Supriyanto, Eko Amini, Neda Abdul Majid, Fadzilah Adibah Jaganathan, Saravana Kumar |
| author_facet | Marvibaigi, Mohsen Supriyanto, Eko Amini, Neda Abdul Majid, Fadzilah Adibah Jaganathan, Saravana Kumar |
| author_sort | Marvibaigi, Mohsen |
| collection | ePrints |
| description | Breast cancer is among the most frequent types of cancer in women worldwide. Current conventional treatment options are accompanied by side effects. Mistletoe is amongst the important herbal medicines traditionally used as complementary remedies. An increasing number of studies have reported anticancer activity of mistletoe extracts on breast cancer cells and animal models. Some recent evidence suggests that cytotoxic activity of mistletoe may be mediated through different mechanisms. These findings provide a good base for clinical trials. Various studies on mistletoe therapy for breast cancer patients revealed similar findings concerning possible benefits on survival time, health-related quality of life (HRQoL), remission rate, and alleviating adverse reactions to conventional therapy. This review provides an overview of the recent findings on preclinical experiments and clinical trials of mistletoe for its cytotoxic and antitumor activity and its effect on HRQoL in breast cancer patients. Moreover, studies investigating molecular and cellular mechanisms underlying antitumor activity of mistletoe are discussed in this paper. The analyzed trials provided evidence that there might be a combination of pharmacological and motivational aspects mediated by the mistletoe extract application which may contribute to the clinical benefit and positive outcome such as improved HRQoL and self-regulation in breast cancer patients. |
| first_indexed | 2024-03-05T19:35:08Z |
| format | Article |
| id | utm.eprints-54555 |
| institution | Universiti Teknologi Malaysia - ePrints |
| last_indexed | 2024-03-05T19:35:08Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | utm.eprints-545552017-09-12T08:28:03Z http://eprints.utm.my/54555/ Preclinical and clinical effects of mistletoe against breast cancer Marvibaigi, Mohsen Supriyanto, Eko Amini, Neda Abdul Majid, Fadzilah Adibah Jaganathan, Saravana Kumar QH Natural history Breast cancer is among the most frequent types of cancer in women worldwide. Current conventional treatment options are accompanied by side effects. Mistletoe is amongst the important herbal medicines traditionally used as complementary remedies. An increasing number of studies have reported anticancer activity of mistletoe extracts on breast cancer cells and animal models. Some recent evidence suggests that cytotoxic activity of mistletoe may be mediated through different mechanisms. These findings provide a good base for clinical trials. Various studies on mistletoe therapy for breast cancer patients revealed similar findings concerning possible benefits on survival time, health-related quality of life (HRQoL), remission rate, and alleviating adverse reactions to conventional therapy. This review provides an overview of the recent findings on preclinical experiments and clinical trials of mistletoe for its cytotoxic and antitumor activity and its effect on HRQoL in breast cancer patients. Moreover, studies investigating molecular and cellular mechanisms underlying antitumor activity of mistletoe are discussed in this paper. The analyzed trials provided evidence that there might be a combination of pharmacological and motivational aspects mediated by the mistletoe extract application which may contribute to the clinical benefit and positive outcome such as improved HRQoL and self-regulation in breast cancer patients. 2014 Article PeerReviewed Marvibaigi, Mohsen and Supriyanto, Eko and Amini, Neda and Abdul Majid, Fadzilah Adibah and Jaganathan, Saravana Kumar (2014) Preclinical and clinical effects of mistletoe against breast cancer. BIOMED RESEARCH INTERNATIONAL . ISSN 2314-6133 http://dx.doi.org/10.1155/2014/785479 |
| spellingShingle | QH Natural history Marvibaigi, Mohsen Supriyanto, Eko Amini, Neda Abdul Majid, Fadzilah Adibah Jaganathan, Saravana Kumar Preclinical and clinical effects of mistletoe against breast cancer |
| title | Preclinical and clinical effects of mistletoe against breast cancer |
| title_full | Preclinical and clinical effects of mistletoe against breast cancer |
| title_fullStr | Preclinical and clinical effects of mistletoe against breast cancer |
| title_full_unstemmed | Preclinical and clinical effects of mistletoe against breast cancer |
| title_short | Preclinical and clinical effects of mistletoe against breast cancer |
| title_sort | preclinical and clinical effects of mistletoe against breast cancer |
| topic | QH Natural history |
| work_keys_str_mv | AT marvibaigimohsen preclinicalandclinicaleffectsofmistletoeagainstbreastcancer AT supriyantoeko preclinicalandclinicaleffectsofmistletoeagainstbreastcancer AT aminineda preclinicalandclinicaleffectsofmistletoeagainstbreastcancer AT abdulmajidfadzilahadibah preclinicalandclinicaleffectsofmistletoeagainstbreastcancer AT jaganathansaravanakumar preclinicalandclinicaleffectsofmistletoeagainstbreastcancer |